NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $38.25 Average Price Target from Brokerages

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $38.25.

Several research firms recently commented on NRXP. D. Boral Capital reaffirmed a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, May 5th. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. Ascendiant Capital Markets raised their target price on NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. BTIG Research reissued a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, March 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of NRx Pharmaceuticals in a research report on Monday, April 27th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Bleakley Financial Group LLC purchased a new position in NRx Pharmaceuticals in the fourth quarter worth about $318,000. Anson Funds Management LP boosted its position in NRx Pharmaceuticals by 26.2% in the third quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock worth $6,683,000 after purchasing an additional 420,129 shares during the last quarter. Global Retirement Partners LLC bought a new position in shares of NRx Pharmaceuticals in the fourth quarter worth about $107,000. One Wealth Management Investment & Advisory Services LLC raised its stake in shares of NRx Pharmaceuticals by 35.3% in the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock worth $103,000 after buying an additional 9,882 shares during the period. Finally, Sjbenen Advisory LLC bought a new position in shares of NRx Pharmaceuticals in the fourth quarter worth about $41,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Price Performance

NRx Pharmaceuticals stock opened at $4.09 on Friday. NRx Pharmaceuticals has a one year low of $1.62 and a one year high of $5.05. The stock has a market capitalization of $148.18 million, a PE ratio of -3.75 and a beta of 2.14. The business’s fifty day moving average is $3.56 and its 200 day moving average is $2.63.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. The business had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $19.43 million. As a group, sell-side analysts expect that NRx Pharmaceuticals will post -0.3 EPS for the current fiscal year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.